Newsroom

In oncology, many manufacturers go into niche indications, where there are very specific tumors, and then they opt for..

In this two-part blog series, we interview Bart Heeg, Vice President HEOR and Founder at Ingress Health (A Cytel..

In this interview with Thomas Wilke, Principal Scientist at Ingress-Health (a Cytel company), we talk to him about his..

COVID-19 has created extreme uncertainties -- a dearth of historical information combined with the need for safety,..

A credible evidence base is needed to support and document the economic value of new technologies and therapeutic..

Single arm trials are emerging as an accepted way of assessing a new treatment intervention. They establish clinical..

Recently a biotech approached Cytel for support with a Phase 2 Study in oncology. Regulators had requested a natural..

Cytel is conducting two pilot projects on head-to-head comparisons using real world data. These projects in oncology..

A new peer-reviewed article co-authored by several Cytel scientists re-examines the way in which adaptive trials are..